- Home
- ZYME vs TRNS Comparison
ZYME vs TRNS Comparison
Compare ZYME & TRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- TRNS
- Stock Information
- Founded
- ZYME 2003
- TRNS 1964
- Country
- ZYME United States
- TRNS United States
- Employees
- ZYME 290
- TRNS N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- TRNS Electrical Products
- Sector
- ZYME Health Care
- TRNS Industrials
- Exchange
- ZYME Nasdaq
- TRNS Nasdaq
- Market Cap
- ZYME 956.0M
- TRNS 982.9M
- IPO Year
- ZYME 2017
- TRNS N/A
- Fundamental
- Price
- ZYME $13.88
- TRNS $100.34
- Analyst Decision
- ZYME Buy
- TRNS Strong Buy
- Analyst Count
- ZYME 6
- TRNS 4
- Target Price
- ZYME $19.17
- TRNS $122.75
- AVG Volume (30 Days)
- ZYME 565.8K
- TRNS 73.3K
- Earning Date
- ZYME 03-05-2025
- TRNS 01-27-2025
- Dividend Yield
- ZYME N/A
- TRNS N/A
- EPS Growth
- ZYME N/A
- TRNS 77.19
- EPS
- ZYME N/A
- TRNS 1.98
- Revenue
- ZYME $62,199,000.00
- TRNS $270,612,000.00
- Revenue This Year
- ZYME $21.53
- TRNS $10.53
- Revenue Next Year
- ZYME N/A
- TRNS $7.78
- P/E Ratio
- ZYME N/A
- TRNS $50.70
- Revenue Growth
- ZYME N/A
- TRNS 11.42
- 52 Week Low
- ZYME $7.97
- TRNS $94.29
- 52 Week High
- ZYME $17.70
- TRNS $147.12
- Technical
- Relative Strength Index (RSI)
- ZYME 48.04
- TRNS 39.04
- Support Level
- ZYME $12.80
- TRNS $99.38
- Resistance Level
- ZYME $14.63
- TRNS $106.74
- Average True Range (ATR)
- ZYME 0.85
- TRNS 3.75
- MACD
- ZYME -0.04
- TRNS -0.44
- Stochastic Oscillator
- ZYME 25.29
- TRNS 8.98
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About TRNS Transcat Inc.
Transcat Inc is involved in providing calibration and laboratory instrument services and distribution of test, measurement, and control instrumentation. Its product and services portfolio consists of calibration instruments, dimensional measuring tools, Electrical test instruments, pressure measurement, etc. The firm has Service and Distribution operating segments. It derives the majority of its revenues from the Service segment. The firm promotes and sells its products under brand names such as Estech, FLIR, Fluke, Keysight, and Megger among others. It serves to pharmaceutical, industrial manufacturing, energy, and chemical process industries.